PTN

Palatin Technologies, Inc. focuses on developing treatments for obesity and metabolic diseases by targeting the melanocortin receptor (MCR) system, which regulates energy balance, metabolism, and inflammation. The company advances novel selective MC4R agonists, including small molecules and peptides, with a particular emphasis on rare neuroendocrine disorders such as hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome. Palatin operates primarily in the biotechnology sector, aiming to address unmet medical needs in these specialized areas.